Get the Stockscreener App
12.36
1.90%
-0.24
After Hours:
12.47
0.11
+0.89%
Replimune Group Inc stock is traded at $12.36, with a volume of 1.65M.
It is down -1.90% in the last 24 hours and down -21.77% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
See More
Previous Close:
$12.60
Open:
$12.63
24h Volume:
1.65M
Relative Volume:
0.38
Market Cap:
$1.16B
Revenue:
-
Net Income/Loss:
$-313.94M
P/E Ratio:
-3.5254
EPS:
-3.506
Net Cash Flow:
$-284.57M
1W Performance:
-5.43%
1M Performance:
-21.77%
6M Performance:
+63.49%
1Y Performance:
+205.19%
1-Day Range:
$12.30
$12.80
1-Week Range:
$12.07
$13.63
52-Week Range:
$1.50
$16.33
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
12.36 | 1.16B | 0 | -313.94M | -284.57M | -3.506 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| Apr-13-26 | Downgrade | H.C. Wainwright | Buy → Sell |
| Apr-13-26 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-13-26 | Downgrade | Jefferies | Buy → Hold |
| Apr-13-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-13-26 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-10-26 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-03-25 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| Oct-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-20-25 | Upgrade | Wedbush | Neutral → Outperform |
| Sep-19-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
Understanding the Setup: (REPL) and Scalable Risk - Stock Traders Daily
Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval - Stocktwits
Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before October 5, 2026 - ACCESS Newswire
REPL STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Class Action Filed Against Replimune Group, Inc. (REPL) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Class action lawsuit filed against Replimune af... - Pluang
ETFs Investing in Replimune Group, Inc. Stocks - TradingView
Securities Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Levi & Korsinsky Represents Shareholders - accessnewswire.com
Howard G. Smith joins probe into Replimune fraud after FDA BLA rejection - scanx.trade
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - accessnewswire.com
Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026Contact Levi & Korsinsky - accessnewswire.com
REPL Stock Clocks Worst Day In Over 3 Months — New FDA Documents Leave Wall Street Awaiting Another Rejection For Cancer Drug - Stocktwits
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, - GlobeNewswire
Replimune faces securities lawsuit over alleged misleading FDA trial data claims on RP1 drug resubmission. - Pluang
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - PR Newswire
Replimune stock falls 3.79 percent as losses persist - AD HOC NEWS
Investors Urged to Contact Levi & Korsinsky For Information Before October 5, 2026Replimune Group, Inc. (REPL) - ACCESS Newswire
Levi & Korsinsky Notifies Replimune Group, Inc. (REPL) InvestorsLead Plaintiff Deadline on October 5, 2026 - ACCESS Newswire
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class ActionContact the Firm - PR Newswire
Securities Lawsuit Alert: Replimune Group, Inc. (REPL)Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
Replimune stock gains as share authorization doubles - AD HOC NEWS
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of October 5, 2026 Deadline - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors - GlobeNewswire
REPL Shareholders Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Replimune Group Inc (NASDAQ: REPL) Share Price, REPL Stock News, REPL Share Price & Updates - kalkine.com.au
Replimune Group, Inc. (REPL) Stock Analysis: A Potential 51.52% Upside In Biotech Innovations - DirectorsTalk Interviews
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026 - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Replimune shares plunge 84% after FDA rejects R... - Pluang
REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action LawsuitInvestors With Losses May Contact SueWallSt - PR Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. LawsuitREPL - PR Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of October 5, 2026 Deadline - ACCESS Newswire
REPL Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors – Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire
REPL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits
REPL Stock Lost 19% Of Its Value Today – Why Did The FDA Refuse Approval For Its Experimental Melanoma Drug? - Stocktwits
REPL Stock DropRobbins LLP Reminds Investors They May Be - GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class ActionContact Levi & Korsinsky - Business Wire
REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REPL: TUDRIQEV launch targets rapid adoption in key accounts, with expansion and new indications ahead - TradingView
DEADLINE ALERT for REPL, DVLT, and UWMC: The Law Offices of - GlobeNewswire
Replimune faces class action over alleged nondi... - Pluang
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):